Cytomegalovirus Infection in Pediatric Solid Organ Transplant Recipients: a Focus on Prevention

被引:9
作者
Tsai, Karen C. [1 ]
Danziger-Isakov, Lara A. [2 ]
Banach, David B. [1 ]
机构
[1] Yale Univ, Sch Med, 800 Howard Ave, New Haven, CT USA
[2] Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave,MLC 7017, Cincinnati, OH 45229 USA
关键词
Cytomegalovirus; CMV; Pediatric; Solid organ transplantation; Prophylaxis; Preemptive; Hybrid; HEMATOPOIETIC STEM-CELL; LIVER-TRANSPLANT; PREEMPTIVE THERAPY; RISK-FACTORS; GRAFT LOSS; INTRAVENOUS GANCICLOVIR; ANTITHYMOCYTE GLOBULIN; ORAL VALGANCICLOVIR; PRACTICE GUIDELINE; MEDIATED-IMMUNITY;
D O I
10.1007/s11908-015-0511-8
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Solid organ transplantation is a life-saving procedure that has changed the prognosis for infants and children with end-stage organ disease. Cytomegalovirus (CMV) is one of the most common infections that occur after organ transplantation in pediatric patients, yet the standard of care for CMV prevention remains unclear. We review the literature regarding CMV disease effects, risk factors, diagnostics, prevention strategies, and antiviral treatment in pediatric solid organ transplantation. This discussion focuses on the current prevention strategies: prophylaxis, preemptive, and hybrid therapy, as well as novel strategies that may help better prevent the CMV disease in the pediatric solid organ transplant population.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 82 条
[1]   Delayed-onset primary cytomegalovirus disease after liver transplantation [J].
Arthurs, Supha K. ;
Eid, Albert J. ;
Pedersen, Rachel A. ;
Dierichising, Ross A. ;
Kremers, Walter K. ;
Patel, Robin ;
Razonable, Raymund R. .
LIVER TRANSPLANTATION, 2007, 13 (12) :1703-1709
[2]   Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients [J].
Asberg, A. ;
Humar, A. ;
Rollag, H. ;
Jardine, A. G. ;
Mouas, H. ;
Pescovitz, M. D. ;
Sgarabotto, D. ;
Tuncer, M. ;
Noronha, I. L. ;
Hartmann, A. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 (09) :2106-2113
[3]   New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients [J].
Asberg, A. ;
Bjerre, A. ;
Neely, M. .
PEDIATRIC TRANSPLANTATION, 2014, 18 (01) :103-111
[4]   Long-Term Outcomes of CMV Disease Treatment with Valganciclovir Versus IV Ganciclovir in Solid Organ Transplant Recipients [J].
Asberg, A. ;
Humar, A. ;
Jardine, A. G. ;
Rollag, H. ;
Pescovitz, M. D. ;
Mouas, H. ;
Bignamini, A. ;
Toez, H. ;
Dittmer, I. ;
Montejo, M. ;
Hartmann, A. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 (05) :1205-1213
[5]   Cytomegalovirus Seroprevalence in the United States: The National Health and Nutrition Examination Surveys, 1988-2004 [J].
Bate, Sheri Lewis ;
Dollard, Sheila C. ;
Cannon, Michael J. .
CLINICAL INFECTIOUS DISEASES, 2010, 50 (11) :1439-1447
[6]   Cytomegalovirus in Solid Organ Transplantation: Epidemiology, Prevention, and Treatment [J].
Beam, Elena ;
Razonable, Raymund R. .
CURRENT INFECTIOUS DISEASE REPORTS, 2012, 14 (06) :633-641
[7]   Impact of a Preemptive Strategy After 3 Months of Valganciclovir Cytomegalovirus Prophylaxis in Kidney Transplant Recipients [J].
Blanco, Noemie Boillat ;
Pascual, Manuel ;
Venetz, Jean-Pierre ;
Nseir, Ghaleb ;
Meylan, Pascal R. ;
Manuel, Oriol .
TRANSPLANTATION, 2011, 91 (02) :251-255
[8]   Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients [J].
Bodro, Marta ;
Sabe, Nuria ;
Llado, Laura ;
Baliellas, Carme ;
Niubo, Jordi ;
Castellote, Jose ;
Fabregat, Joan ;
Rafecas, Antoni ;
Carratala, Jordi .
LIVER TRANSPLANTATION, 2012, 18 (09) :1093-1099
[9]   Association of Cytomegalovirus Infection and Disease With Death and Graft Loss After Liver Transplant in High-Risk Recipients [J].
Bosch, W. ;
Heckman, M. G. ;
Diehl, N. N. ;
Shalev, J. A. ;
Pungpapong, S. ;
Hellinger, W. C. .
AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 (10) :2181-2189
[10]  
BOWMAN JS, 1991, CLIN TRANSPLANT, V5, P294